Efficacy of tegoprazan versus esomeprazole in treatment of reflux esophagitis and analysis of influencing factors for treatment failure

Objective To compare the efficacy of tegoprazan and esomeprazole in treatment of reflux esophagitis (RE) and analyze the influencing factors for treatment failure.

Methods A total of 120 RE patients were selected as study subjects and divided into control group (treated with esomeprazole) and observation group (treated with tegoprazan) using random number table method, with 60 cases in each group. The clinical efficacy and gastroscopic efficacy of the two groups were compared. Based on the gastroscopic assessment results, the patients were divided into failure group (26 cases) and success group (94 cases). The clinical data of the failure group and the success group were collected and compared. Multivariate Logistic regression analysis was used to screen the influencing factors for treatment failure in RE patients.

Results The total clinical effective rate in the observation group was 93.33% (56/60), which was higher than 76.67%(46/60) in the control group (P < 0.05). The total effective rate under gastroscopy in the observation group was 88.33%(53/60), which was higher than 68.33%(41/60) in the control group, and the difference was statistically significant (P < 0.05). The proportions of patients with body mass index (BMI)>28 kg/m², diabetes, a family history, Helicobacter pylori (Hp) infection, Los Angeles classification (LA classification) of gastroesophageal reflux disease (GERD) grade C to D, and treated with esomeprazole in the failure group were all higher than those in the success group, and the differences were statistically significant (P < 0.05). Multivariate Logistic regression analysis showed that BMI>28 kg/m², concomitant diabetes, LA classification grade C to D, and treatment with esomeprazole were all independent risk factors for treatment failure in RE patients (P < 0.05).

Conclusion Tegoprazan has a significant clinical effect in treatment of RE, and its efficacy is superior to that of esomeprazole. BMI>28 kg/m², concomitant diabetes, LA classification grade C to D, and treatment with esomeprazole are all risk factors for treatment failure in RE patients.